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Introduction
Antibodies directed against self-antigens are frequently
found in the serum of patients suffering from autoimmune
diseases. The presence of autoantibodies has raised a
series of fundamental questions for those who seek to
understand the pathogenesis of these disorders. Are the
processes that regulate the production of mature B-cell
receptors functioning aberrantly in autoimmunity? If dys-
regulation is present, are there additional processes of
B-cell proliferation and/or antigen response that serve to
augment the deleterious properties of autoantibodies?
Moreover, are these autoantibodies the product of non-
specific B-cell stimulation (a bystander effect) or of an
antigen-driven response? If the latter, what is the identity
of the inciting antigen(s) and/or driving antigen(s)?
Antibody assembly and B-cell development
Antibodies are the product of a complex set of gene
rearrangements, somatic hypermutation, and receptor-
driven selection. These processes are carefully regulated
during development, during ontogeny, and during the
response to antigen. Each of these processes can alter
the composition or the sequence of the antibody; hence,
when studied as a population, or even individually, analysis
of autoantibody sequences can indicate whether they lie
outside the normal range exhibited by conventional anti-
bodies and thus are intrinsically aberrant. Sequence analy-
sis of individual antibodies can indicate the stages of
development through which the antibody-producing B cell
has passed. An analysis of a population of sequences can
demonstrate whether the response is polyclonal, pointing
to nonspecific stimulation, or oligoclonal, suggesting
antigen drive.
B cells develop in the bone marrow and fetal liver, and
mature in the peripheral lymphoid organs [1,2]. The
immunoglobulins that they produce contain two heavy (H)
and two light (L) polypeptide chains. Each chain includes
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a variable (V) domain that helps define the antigen speci-
ficity of the mature antibody. In the bone marrow and fetal
liver, B-cell progenitors initiate creation of an H chain
V domain by joining one of 27 diversity (DH) gene seg-
ments (belonging to one of seven families) to one of six
joining (JH) gene segments, and then adding one of
approximately 50 variable gene segments (from one of
seven families) to the formed DJ join [3,4]. Creation of a
translatable H chain allows the developing B cell to
express the H chain associated with a surrogate chain to
form the pre-B-cell receptor, and in a later stage the H
chain associates with a translatable light chain V → J
rearrangement product to form a mature immunoglobulin.
Expression of immunoglobulin on the cell surface allows
receptor-based selection of the B cell. The organization of
the κ and λ L chain loci is conducive to repeated cycles of
V → J rearrangement, enabling the system to edit deleteri-
ous receptors by replacing the L chain [5,6]. Editing of the
H chain is also possible [7].
Immunoglobulin V domains each contain three β loops of
highly variable sequence (the complementarity determin-
ing regions [CDRs]) and four β sheets of conserved
framework sequence [8]. Of these, the HCDR3 and, to a
lesser extent, the LCDR3 are the most critical because
they are created directly by V(D)J joining and they lie at
the center of the antigen binding site, where they typically
play a critical role in defining the antigen specificity of the
antibody (reviewed in [9]). Within HCDR3, DH gene seg-
ments have the potential to be read in any one of six
reading frames, which magnifies the potential for combina-
torial diversity in the H chain [10]. Additional diversity is
introduced by flexibility in the site of gene segment
rearrangement and by the somatic addition of nontem-
plated (N regions) and templated (P junctions) nucleotides
at the rearrangement junctions [9].
The composition of the antibody repertoire is
regulated and constrained
Although at first glance the diversity of the antibody reper-
toire appears random, a closer inspection reveals evi-
dence of bias, constraints, and restrictions. Gene segment
utilization is nonrandom, with a preference in the adult for
a small set of HV and LV gene segments; for example, in
the heavy chain members of the DH3, DH2 and DH6 fami-
lies, and JH4, JH5 and JH6 families are most prevalent
(reviewed in [11,12]). These preferences can change
during ontogeny, with D7, JH3 and JH4 gene segments
over-represented during the second trimester of fetal life.
Preference for sets of gene segments in a population of
cells from a given disease that do not reflect the bias seen
in healthy individuals can result from abnormal regulation
of B-cell development, from outgrowths of cells derived
from early ontogeny, or from antigen-driven selection of a
rare subset of the normal repertoire. Nonrandom use of V
gene segments in autoantibodies produced by a subset of
B-cell chronic lymphocytic leukemia cells raised the possi-
bility that transformation had occurred in the fetal period
[13]. However, a more current view holds that the bias in
gene segment utilization in these autoimmune tumor cells
reflects antigen selection [14].
Autoantibodies may violate constraints
placed on the normal antibody repertoire
In antibodies from healthy individuals, HCDR3 sequences
are enriched for neutral, hydrophilic amino acids, including
tyrosine, glycine, and serine (reviewed in [15]). Hydropho-
bic and charged residues, especially those with a positive
charge such as arginine, lysine, and histidine, are quite
rare. This bias is due, in part, to a preference for a single
DH reading frame, RF1, which is enriched for these amino
acids. However, use of charged amino acids is quite rare
even in antibodies with extensive N addition. Antibodies
against double-stranded DNA that contain arginine in
HCDR3 [16] are thus not only abnormal in their specificity,
but also in their composition; they potentially reflect a
failure to limit reading frame preference during rearrange-
ment, a possible factor in enhancing susceptibility for the
development of autoantibodies [17].
The length distribution of LCDR3 and HCDR3, and hence
the structure of the antigen binding site, also appears to
be regulated. Human κ chain LCDR3s, for example, are
typically nine amino acids long, whereas HCDR3 lengths
range from six to 20 amino acids in the fetus and from six
to 28 amino acids in the adult [12,18,19]. The mecha-
nisms that control length are incompletely understood.
Accumulations of B cells are found in the diseased syn-
ovium of patients with rheumatoid arthritis and these cells
often produce significant quantities of antibody, much of
which has rheumatoid factor activity. In these patients, the
frequency of κ chain LCDR3s with lengths outside the
normal range is increased, which could be the product of
an abnormal pattern of production [18,20].
Receptor editing
Receptor editing is a mechanism that could be used to
prevent the production of abnormal antibodies. Con-
versely, it has the potential to introduce abnormalities at an
intermediate stage in B-cell development. Evidence of an
enhancement of receptor editing in autoimmune disease
has been sought through analysis of J utilization in
L chains on the presumption that enrichment for down-
stream J gene segments would reflect repeated rearrange-
ment and editing [21]. Other studies have sought
evidence of prolonged activity of the recombination
machinery [20]. Proof of abnormal receptor editing func-
tion in autoimmune disease has been elusive, although it
remains an attractive possibility.
All of the aforementioned ontological and developmental
constraints in the creation of the mature B-cell repertoireArthritis Research    Vol 4 No 2 Link and Schroeder
play a crucial role in shaping the population of antibodies
in healthy individuals, and each process is a potential
target for dysregulation. Mechanisms used for affinity mat-
uration in an antigen-driven response also have the poten-
tial to create aberrant or pathogenic antibodies. It should
be noted that these possibilities are not mutually exclusive.
The role of affinity maturation
In peripheral lymph nodes, B cells with antibodies spe-
cific for antigen can, with appropriate T-cell help, form
germinal centers. The variable domains in these organs
typically undergo somatic hypermutation, which is the
basis for affinity maturation. The mutations initially appear
to be scattered throughout the variable domain, although
with an emphasis on RGYW hot spots [22]. B cells that
have gained the highest affinity for antigen subsequently
outcompete B cells with lower affinity for antigen pre-
sented on the surface of the follicular dendritic cells from
which the B cells receive signals necessary for survival.
Associated with this process is enrichment for replace-
ment mutations in the CDRs with conservation of
sequence in the frameworks, which maintains the struc-
tural stability of the antigen binding site [23]. One
product of sequential mutation is an accumulation of
sequences that share common mutations, yet differ at
other sites. Sequences derived from a common ancestor
that contain distinguishing mutations are termed ‘clonally
related’ and are another marker of an antigen-driven
humoral response.
Mutations in autoantibody sequences suggest that the
B cells that produced them have passed through a germi-
nal center. Random mutations in the sequence, as evi-
denced by a moderate amino acid replacement to silent
site substitution ratio in the affected codons, would
support a bystander effect in the stimulation and growth of
autoreactive B cells. In sequences derived from cloning of
transcripts from diseased rheumatoid synovial tissue [18]
and in sequences obtained by single cell analysis from
germinal center-like structures in rheumatoid synovium
[24] there is evidence of preservation of the frameworks
with divergence in the CDRs, supportive of an antigen-
driven response. Clonally related sequences have also
been found in synovial fluid and in the synovium, further
supporting antigen drive as the impetus for B-cell prolifer-
ation and immunoglobulin production in the diseased syn-
ovium [24,25].
Studies of the type described have been carried out in a
number of autoimmune diseases. Together, the evidence
supports the view that autoantibody production in auto-
immune disease is antigen driven. The observation that
many of these autoantibody sequences carry features that
are uncommon in antibodies from healthy individuals also
supports the view that regulation of the repertoire is
abnormal in a number of autoimmune diseases.
Conclusion
Although there is strong evidence that the antibody
response in many autoimmune diseases is antigen driven, a
full understanding of the mechanisms that normally con-
strain the repertoire and knowledge of the defects in these
mechanisms that allow the production of autoantibodies, as
well as the nature of the inciting and driving antigen(s), has
yet to be achieved. Elucidation of these mechanisms as well
as identification of the inciting antigen through use of tech-
niques such as single cell analysis and phage display
systems may provide new insight into the pathogenesis,
treatment, and prevention of these puzzling diseases.
Acknowledgements
This work was supported, in part, by NIH AI07051, AI47322, and
AI48115.
References
1. Burrows PD, Cooper MD: B cell development and differentia-
tion. Curr Opin Immunol 1997, 9:239-244.
2. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R,
Lamers MC, Carsetti R: B cell development in the spleen takes
place in discrete steps and is determined by the quality of B
cell receptor-derived signals. J Exp Med 1999, 190:75-89.
3. Yancopoulos GD, Alt FW: Regulation of the assembly and
expression of variable-region genes. Annu Rev Immunol 1986,
4:339-368.
4. Matsuda F, Ishii K, Bourvagnet P, Kuma K, Hayashida H, Miyata T,
Honjo T: The complete nucleotide sequence of the human
immunoglobulin heavy chain variable region locus. J Exp Med
1998, 188:2151-2162.
5. Tiegs SL, Russell DM, Nemazee D: Receptor editing in self-
reactive bone marrow B cells. J Exp Med 1993,  177:1009-
1020.
6. Pelanda R, Schwers S, Sonoda E, Torres RM, Nemazee D,
Rajewsky K: Receptor editing in a transgenic mouse model:
site, efficiency, and role in B cell tolerance and antibody diver-
sification. Immunity 1997, 7:765-775.
7. Wilson PC, Wilson K, Liu YJ, Banchereau J, Pascual V, Capra JD:
Receptor revision of immunoglobulin heavy chain variable
region genes in normal human B lymphocytes. J Exp Med
2000, 191:1881-1894.
8. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C:
Sequences of proteins of immunological interest. Bethesda,
National Institutes of Health; 1991.
9. Kirkham PM, Schroeder HW Jr: Antibody structure and the evo-
lution of immunoglobulin V gene segments. Semin Immunol
1994, 6:347-360.
10. Padlan EA: Anatomy of the antibody molecule. Mol Immunol
1994, 31:169-217.
11. Schroeder HW Jr, Ippolito GC, Shiokawa S: Regulation of the
antibody repertoire through control of HCDR3 diversity.
Vaccine 1998, 16:1363-1368.
12. Shiokawa S, Mortari F, Lima JO, Nunez C, Bertrand FE III, Kirkham
PM, Zhu S, Dasanayake AP, Schroeder HW Jr: IgM heavy chain
complementarity-determining region 3 diversity is con-
strained by genetic and somatic mechanisms until two
months after birth. J Immunol 1999, 162:6060-6070.
13. Kipps TJ, Tomhave E, Pratt LF, Chen PP, Carson DA: Develop-
mentally restricted VH gene is expressed at high frequency in
Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA 1989,
86:5913-5917.
14. Damle RN, Fais F, Ghiotto F, Valetto A, Albesiano E, Wasil T,
Batliwalla FM, Allen SL, Schulman P, Vinciguerra VP, Rai KR,
Gregersen, PK, Ferrarini M, Chiorazzi N: Chronic lymphocytic
leukemia: a proliferation of B cells at two distinct stages of
differentiation. Curr Topics Microbiol Immunol 2000, 252:285-
292.
15. Ivanov IJ, Link JM, Ippolito GC, Schroeder HW: Constraints on
hydropathicity and sequence composition of HCDR3 are con-
served across evolution. In The Antibodies. Edited by Capra JD,Available online http://arthritis-research.com/content/4/2/080
Zanetti M. Amsterdam: Harwood Academic Publishers; 2002 (in
press).
16. Shlomchik MJ, Mascelli MA, Shan H, Radic MZ, Pisetsky DS,
Marshak-Rothstein A, Weigert MG: Anti-DNA antibodies from
autoimmune mice arise by clonal expansion and somatic
mutation. J Exp Med 1990, 171:265-297.
17. Klonowski KD, Primiano LL, Monestier M: Atypical VH-D-JH
rearrangements in newborn autoimmune MRL mice. J
Immunol 1999, 162:1566-1572.
18. Bridges SL Jr, Lee SK, Johnson ML, Lavelle JC, Fowler PG,
Koopman WJ, Schroeder HW Jr: Somatic mutation and CDR3
lengths of immunoglobulin kappa light chains expressed in
patients with rheumatoid arthritis and in normal individuals. J
Clin Invest 1995, 96:831-841.
19. Brezinschek HP, Brezinschek RI, Lipsky PE: Analysis of the
heavy chain repertoire of human peripheral B cells using
single-cell polymerase chain reaction. J Immunol 1995, 155:
190-202.
20. Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB,
Staudt LM, Young JW, Nussenzweig MC: Human B cells
expressing surrogate light chains show increased receptor
editing and accumulate in rheumatoid synovia. Nat Immunol
2000, 1:187-188.
21. Hansen A, Dorner T, Lipsky PE: Use of immunoglobulin vari-
able-region genes by normal subjects and patients with sys-
temic lupus erythematosus. Int Arch Allergy Immunol 2000,
123:36-45.
22. Dorner T, Foster SJ, Farner NL, Lipsky PE: Somatic hypermuta-
tion of human immunoglobulin heavy chain genes: targeting
of RGYW motifs on both DNA strands. Eur J Immunol 1998, 28:
3384-3396.
23. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL,
Weigert MG: The role of clonal selection and somatic muta-
tion in autoimmunity. Nature 1987, 328:805-811.
24. de Boer BA, Voigt I, Kim HJ, Camacho SA, Lipp M, Forster R,
Berek C: Affinity maturation in ectopic germinal centers. Curr
Topics Microbiol Immunol 2000, 251:191-195.
25. Randen I, Brown D, Thompson KM, Hughes-Jones N, Pascual V,
Victor KD, Capra JD, Forre O, Natvig JB: Clonally related IgM
rheumatoid factors undergo affinity maturation in the
rheumatoid synovial tissue. J Immunol 1992, 148:3296-3301.